论文部分内容阅读
目的:探讨重组人白细胞介素15(rhIL-15)对人外周血单个核细胞(PBMC)抗肿瘤效应及T细胞受体(TCR)互补决定区3(CDR3)的影响。方法:应用LDH释放法检测rhIL-15作用前后PBMC对人急性髓系白血病细胞KG1a的杀伤活性。分别以Jurkat和Raji细胞作为阳性和阴性对照,建立TCRCDR3基因扫描技术,并用其检测rhIL-15作用前后5名健康个体T细胞克隆表型。结果:rhIL-15作用后PBMC对KG1a细胞的杀伤活性较rhIL-15作用前明显增强(P<0.05)。基因扫描显示5名健康个体TCRCDR3谱型均呈高斯分布,各家族CDR3表达频率接近,但呈现不同的多态性和长度分布。rhIL-15作用前后5名健康个体T细胞克隆表型无明显变化。结论:rhIL-15能显著提高PBMCs的抗肿瘤效应,并不改变T细胞的克隆表型。
Objective: To investigate the effect of recombinant human interleukin 15 (rhIL-15) on the anti-tumor effect of human peripheral blood mononuclear cells (PBMC) and the complementarity determining region 3 (CDR3) of T cell receptor (TCR). Methods: The killing activity of PBMCs on human acute myeloid leukemia KG1a cells before and after rhIL-15 treatment was detected by LDH release method. Jurkat and Raji cells were used as positive and negative controls, respectively, to establish the TCRCDR3 gene scanning technology, and used to detect the clonal phenotype of T cells in 5 healthy individuals before and after rhIL-15 treatment. RESULTS: The killing activity of PBMC on KG1a cells after rhIL-15 treatment was significantly higher than that before rhIL-15 treatment (P<0.05). Gene scans showed that the TCRCDR3 profiles were Gaussian distribution in 5 healthy individuals. The frequency of CDR3 expression in each family was close, but showed different polymorphism and length distribution. There was no significant change in the clonal phenotype of T cells in 5 healthy individuals before and after rhIL-15 treatment. Conclusion: rhIL-15 can significantly increase the anti-tumor effect of PBMCs without altering the clonal phenotype of T cells.